Amerikanische Gesellschaft für Hirudotherapie

Recurrent Aphthous Stomatitis (Investigational Adjunct)

Investigational adjunct for severe recurrent aphthous stomatitis; topical corticosteroids, chlorhexidine, and (for severe disease) colchicine or systemic immunomodulators remain evidence-based.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for recurrent aphthous stomatitis (canker sores). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for recurrent aphthous stomatitis is investigational and considered inappropriate.
Welche Evidenz existiert?
Tier C (investigational). No published trials; only theoretical mention. Evidence-based therapy for recurrent aphthous stomatitis (canker sores): topical corticosteroid (triamcinolone in Orabase, fluocinonide), topical anesthetics (lidocaine 2%), antimicrobial mouthrinses (chlorhexidine), and systemic therapy (colchicine, dapsone, thalidomide) for severe major aphthous ulcers. Workup for underlying systemic disease (Behcet syndrome, IBD, celiac disease, HIV, hematinic deficiencies) in major or recurrent cases. Most minor canker sores heal in 7-14 days without intervention.
Hauptrisiken
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Worsening of oral inflammation or ulceration
  • Bacterial superinfection of oral ulcers
  • Local skin infection or, rarely, Aeromonas infection if leech placed near mouth
  • Allergic reaction to leech saliva (uncommon)
  • Intraoral leech placement is dangerous and not recommended
  • Trigger of Behcet disease flares if underlying condition present
  • Delay of workup for underlying systemic disease
Wer dies nicht in Betracht ziehen sollte
  • Patients with suspected Behcet syndrome, IBD, celiac disease, or HIV
  • Patients with hematinic deficiencies (iron, folate, B12) not yet replaced
  • Patients with active oral candidiasis or herpes simplex
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not tried topical corticosteroid or antimicrobial mouthrinse
  • Pregnant patients
Was Sie Ihren Kliniker fragen sollten
  • Have I been worked up for Behcet syndrome (genital and ocular involvement)?
  • Have I been tested for iron, folate, B12, and celiac disease?
  • Have I tried topical triamcinolone in Orabase or fluocinonide?
  • Am I a candidate for colchicine or systemic therapy for severe major aphthous?
  • Could oral candidiasis or herpes simplex be mimicking aphthous ulcers?
  • What evidence specifically supports leech therapy for canker sores?
  • What is the cost and is it covered by insurance? (typically not covered)
Wann dringende medizinische Versorgung suchen
  • New genital ulcers, eye redness, or skin lesions (possible Behcet syndrome)
  • Abdominal pain, diarrhea, or rectal bleeding (possible inflammatory bowel disease)
  • Severe ulcers with high fever and difficulty swallowing
  • Ulcers persisting more than 3 weeks (rule out malignancy)
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

  • This is NOT FDA-cleared for recurrent aphthous stomatitis or canker sores.
  • Theoretical mention does NOT establish efficacy versus topical corticosteroid, antimicrobial mouthrinse, or colchicine.
  • It does NOT replace workup for Behcet syndrome, IBD, celiac disease, or hematinic deficiencies.
  • It does NOT substitute for evidence-based topical therapy.
  • It does NOT mean intraoral leech application is safe or appropriate.

Clinical Profile

Category
other
ICD-10
K12.0, K12.04
Safety tier
high

Evidence Summary

Recurrent aphthous stomatitis (RAS) is recurrent painful oral ulcers, classified as minor, major, or herpetiform. Evidence-based topical therapy includes triamcinolone or clobetasol in adhesive bases, chlorhexidine rinses, topical anesthetics, and topical sucralfate. Severe or major RAS may warrant colchicine, dapsone, thalidomide (with strict regulatory controls), or systemic corticosteroids. Workup excludes Behcet disease, celiac disease, nutritional deficiencies (B12, folate, iron, zinc), HIV, and inflammatory bowel disease in atypical or severe cases. No published controlled trials of hirudotherapy exist for RAS. Oral mucosal placement of leeches is anatomically inappropriate and uniquely dangerous (airway, swallowing, hemorrhage); any rationale must be extra-oral application without plausible mucosal-targeted mechanism.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Intra-oral placement (absolute — airway and hemorrhage risk)
  • Lip placement
  • Active major RAS or herpetiform RAS with confluent ulcers
  • Behcet disease without rheumatology workup
  • Underlying nutritional deficiency not corrected
  • Immunocompromise (HIV, IBD on immunosuppression)

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Recurrent Aphthous Stomatitis (Investigational Adjunct) — Hirudotherapy Evidence | ASH